An Adaptive Model Predictive Voltage Control for LC-Filtered Voltage Source Inverters

The three-phase inductor and capacitor filter (LC)-filtered voltage source inverter (VSI) is subjected to uncertain and time-variant parameters and disturbances, e.g., due to aging, thermal effects, and load changes. These uncertainties and disturbances have a considerable impact on the performance of a VSI’s control system. It can degrade system performance or even cause system instability. Therefore, considering the effects of all system uncertainties and disturbances in the control system design is necessary. In this respect and to tackle this issue, this paper proposes an adaptive model predictive control (MPC), which consists of three main parts: an MPC, an augmented state-space model, and an adaptive observer. The augmented state-space model considers all system uncertainties and disturbances and lumps them into two disturbance inputs. The proposed adaptive observer determines the lumped disturbance functions, enabling the control system to keep the nominal system performance under different load conditions and parameters uncertainty. Moreover, it provides load-current-sensorless operation of MPC, which reduces the size and cost, and simultaneously improves the system reliability. Finally, MPC selects the proper converter voltage vector that minimizes the tracking errors based on the augmented model and outputs of the adaptive observer. Simulations and experiments on a 5 kW VSI examine the performance of the proposed adaptive MPC under different load conditions and parameter uncertainties and compare them with the conventional MPC

A Systematic Control Design Method with Active Damping Control in Voltage Source Converters

This paper proposes a systematic control design method for active damping control of grid-connected voltage source converters (VSCs). The proposed control method considers the conventional cascaded control loops and improves them by including additional states feedback-based active damping. In such a way, all control gains are lumped into one control gain matrix based on the proposed formulation. The lumping of all control gains into one matrix leads to a linear optimization problem, so different techniques can be used to calculate control gains. This work calculates them by using a simple but effective optimal control theorem as a noteworthy feature. The proposed control method can overcome the challenges of designing multiple control loops, evaluating wide time scale dynamics, and tuning required control parameters. Moreover, direct relationships between the proposed tuning parameters and system well-known stability and performance indicators such as maximum damping factor, minimum damping ratio, and the control efforts are identified, providing good physical insight. Finally, the proposed control structure and optimal gain calculations ensure power converter robustness against uncertainties in the grid’s short-circuit ratio (SCR) and different operating-point conditions. When the grid’s SCR changes from 10 (strong grid condition) to 1 (ultra-weak grid condition), the system under the proposed control method maintains good stability margins and simultaneously provides a fast dynamic response by facilitating the implementation of a high-bandwidth phase-locked loop (PLL). The performance of the proposed control strategy was investigated analytically and practically by conducting eigenvalue analysis, simulations, and experiments

Covalent modification of reduced graphene oxide with piperazine as a novel nanoadsorbent for removal of H2S gas

In the present research, piperazine grafted-reduced graphene oxide RGO-N-(piperazine) was synthesized through a three-step reaction and employed as a highly efficient nanoadsorbent for H2S gas removal. Temperature optimization within the range of 30–90 °C was set which significantly improved the adsorption capacity of the nanoadsorbent. The operational conditions including the initial concentration of H2S (60,000 ppm) with CH4 (15 vol%), H2O (10 vol%), O2 (3 vol%) and the rest by helium gas and gas hour space velocity (GHSV) 4000–6000 h−1 were examined on adsorption capacity. The results of the removal of H2S after 180 min by RGO-N-(piperazine), reduced graphene oxide (RGO), and graphene oxide (GO) were reported as 99.71, 99.18, and 99.38, respectively. Also, the output concentration of H2S after 180 min by RGO-N-(piperazine), RGO, and GO was found to be 170, 488, and 369 ppm, respectively. Both chemisorption and physisorption are suggested as mechanism in which the chemisorption is based on an acid–base reaction between H2S and amine, epoxy, hydroxyl functional groups on the surface of RGO-N-(piperazine), GO, and RGO. The piperazine augmentation of removal percentage can be attributed to the presence of amine functional groups in the case of RGO-N-(piperazine) versus RGO and GO. Finally, analyses of the equilibrium models used to describe the experimental data showed that the three-parameter isotherm equations Toth and Sips provided slightly better fits compared to the three-parameter isotherms

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BackgroundDisorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021.MethodsWe estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined.FindingsGlobally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer.InterpretationAs the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background Disorders affecting the nervous system are diverse and include neurodevelopmental disorders, late-life neurodegeneration, and newly emergent conditions, such as cognitive impairment following COVID-19. Previous publications from the Global Burden of Disease, Injuries, and Risk Factor Study estimated the burden of 15 neurological conditions in 2015 and 2016, but these analyses did not include neurodevelopmental disorders, as defined by the International Classification of Diseases (ICD)-11, or a subset of cases of congenital, neonatal, and infectious conditions that cause neurological damage. Here, we estimate nervous system health loss caused by 37 unique conditions and their associated risk factors globally, regionally, and nationally from 1990 to 2021. Methods We estimated mortality, prevalence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs), with corresponding 95% uncertainty intervals (UIs), by age and sex in 204 countries and territories, from 1990 to 2021. We included morbidity and deaths due to neurological conditions, for which health loss is directly due to damage to the CNS or peripheral nervous system. We also isolated neurological health loss from conditions for which nervous system morbidity is a consequence, but not the primary feature, including a subset of congenital conditions (ie, chromosomal anomalies and congenital birth defects), neonatal conditions (ie, jaundice, preterm birth, and sepsis), infectious diseases (ie, COVID-19, cystic echinococcosis, malaria, syphilis, and Zika virus disease), and diabetic neuropathy. By conducting a sequela-level analysis of the health outcomes for these conditions, only cases where nervous system damage occurred were included, and YLDs were recalculated to isolate the non-fatal burden directly attributable to nervous system health loss. A comorbidity correction was used to calculate total prevalence of all conditions that affect the nervous system combined. Findings Globally, the 37 conditions affecting the nervous system were collectively ranked as the leading group cause of DALYs in 2021 (443 million, 95% UI 378–521), affecting 3·40 billion (3·20–3·62) individuals (43·1%, 40·5–45·9 of the global population); global DALY counts attributed to these conditions increased by 18·2% (8·7–26·7) between 1990 and 2021. Age-standardised rates of deaths per 100 000 people attributed to these conditions decreased from 1990 to 2021 by 33·6% (27·6–38·8), and age-standardised rates of DALYs attributed to these conditions decreased by 27·0% (21·5–32·4). Age-standardised prevalence was almost stable, with a change of 1·5% (0·7–2·4). The ten conditions with the highest age-standardised DALYs in 2021 were stroke, neonatal encephalopathy, migraine, Alzheimer's disease and other dementias, diabetic neuropathy, meningitis, epilepsy, neurological complications due to preterm birth, autism spectrum disorder, and nervous system cancer. Interpretation As the leading cause of overall disease burden in the world, with increasing global DALY counts, effective prevention, treatment, and rehabilitation strategies for disorders affecting the nervous system are needed. Funding Bill & Melinda Gates Foundation